XNYS
BDX
Market cap50bUSD
Oct 08, Last price
182.75USD
1D
1.44%
1Q
20.28%
Jan 2017
43.93%
Name
Becton Dickinson and Co
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Becton, Dickinson and Company (BD) is a global medical technology enterprise engaged in the development, manufacture, and distribution of a comprehensive range of medical supplies, advanced devices, laboratory equipment, and diagnostic products. Its vast product portfolio caters to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public worldwide. The company operates through distinct segments. The BD Medical segment supplies a wide array of products including various peripheral and central intravenous (IV) catheters, vascular care and preparation solutions, needle-free IV connectors, and closed-system drug transfer devices. It also provides hypodermic, anesthesia, and enteral syringes and needles, sharps disposal systems, and prefillable drug delivery solutions. Additionally, this segment offers comprehensive medication management systems, covering IV medication and infusion therapy delivery, compounding workflow, automated dispensing, supply management, and inventory optimization, alongside syringes and pen needles specifically for diabetes care. The BD Life Sciences segment offers diagnostic and research tools, including specimen and blood collection products. Its offerings span automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology, in addition to rapid diagnostic assays, microbiology laboratory automation products, and plated media. For cell analysis, it provides fluorescence-activated cell sorters and analyzers, antibodies, kits, reagent systems, and solutions for single-cell gene expression, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. BD Interventional focuses on surgical and interventional solutions, featuring products for hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and various other surgical applications. This segment also includes items for surgical infection prevention, surgical and laparoscopic instrumentation, peripheral intervention, and specialized urology and critical care products. Founded in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Related entities
Subsidiaries (9)
BECTON DICKINSON Gesellschaft mit beschrankter Haftung
Becton Dickinson Hungary Kereskedelmi Korlatolt Felelossegu Tarsasag
BECTON DICKINSON INDIA PRIVATE LIMITED
Becton Dickinson Luxembourg Finance S.a r.l.
BECTON DICKINSON SA
CAREFUSION DEVELOPMENT PRIVATE LIMITED
Becton Dickinson Euro Finance S.a r.l.
BECTON DICKINSON FRANCE
BECTON, DICKINSON U.K. LIMITED
Key people
Thomas Polen
Chairman of the Board, President, Chief Executive Officer · since 2021
Vitor Roque
Interim Chief Financial Officer · since 2025
William Tozzi
Interim President - Interventional · since 2018
Shana Neal
Chief People Officer, Executive Vice President · since 2022
Richard Byrd
Executive Vice President, President - Interventional Segment · since 2022
Antoine Ezell
Executive Vice President, President, North America, Chief Marketing Officer · since 2020
Michael Feld
Executive Vice President, President - Life Sciences · since 2024
Michael Garrison
Executive Vice President, President - Medical Segment · since 2022
Roland Goette
Executive Vice President, President - EMEA · since 2017
Pavan Mocherla
Executive Vice President, President - Greater Asia · since 2022
Executive Vice President, President - Connected Care Segment · since 2025
David Shan
Executive Vice President, Chief Integrated Supply Chain Officer · since 2023
William Brown
Independent Director · since 2022
Carrie Byington
Independent Director · since 2021
Independent Director · since 2016
Gregory Hayes
Independent Director · since 2025
Independent Director · since 2018
Robert Huffines
Independent Director · since 2025
Independent Director · since 2010
Independent Director · since 2017
Headquarters & legal address
ONE BECTON DRIVE
FRANKLIN LAKES, NJ 07417
US
FRANKLIN LAKES, NJ 07417
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||